Health Benefits and Cost-effectiveness of a Hybrid Screening Strategy for Colorectal Cancer

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 9, 2013, Pages 1158-1166

  Dinh, Tuan ^a   Ladabaum, Uri ^b   Alperin, Peter ^a   Caldwell, Cindy ^c   Smith, Robert ^d   Levin, Theodore R ^c  

^a Archimedes Inc   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

^d AMERICAN CANCER SOCIETY   (United States)

Author keywords

Cancer Screening; Comparative; Cost utility Analysis; Effectiveness; Mixed Screening Strategy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; FAMILY HISTORY; FEMALE; FOLLOW UP; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYPECTOMY; POLYPOSIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; TUMOR GROWTH; TUMOR LOCALIZATION;

ANNUAL FECAL IMMUNOLOGICAL TEST AND COLONOSCOPY AT AGE 66; CANCER SCREENING; CLINICAL OUTCOMES RESEARCH INITIATIVE; COLO; COLONOSCOPY ALONE; COLORECTAL CANCER; COMPARATIVE; CORI; COST-UTILITY ANALYSIS; CRC; EFFECTIVENESS; FECAL IMMUNOLOGICAL TEST; FECAL OCCULT BLOOD TEST; FIT; FIT/COLOX1; FLEXIBLE SIGMOIDOSCOPY; FOBT; FS; GFOBT; GUAIAC-BASED FECAL OCCULT BLOOD TEST; ICER; INCREMENTAL COST-EFFECTIVENESS RATIO; KAISER PERMANENTE NORTHERN CALIFORNIA; KPNC; MIXED SCREENING STRATEGY; QALY; QUALITY-ADJUSTED LIFE YEAR; SEER; SIG; SIGMOIDOSCOPY; SURVEILLANCE EPIDEMIOLOGY AND END RESULTS; THE PERMANENTE MEDICAL GROUP; TPMG;

AGED; CALIFORNIA; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOASSAY; INSURANCE BENEFITS; MALE; MIDDLE AGED; MODELS, STATISTICAL;

EID: 84882741943     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.03.013     Document Type: Article

References (69)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Mandel J.S., Bond J.H., Church T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood: Minnesota Colon Cancer Control Study. N Engl J Med 1993, 328:1365-1371.
3. Selby J.V., Friedman G.D., Quesenberry C.P., et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992, 326:653-657.
4. Atkin W.S., Edwards R., Kralj-Hans I., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010, 375:1624-1633.
5. Winawer S.J., Flehinger B.J., Schottenfeld D., et al. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993, 85:1311-1318.
6. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149:627-637. USPSTF.
7. Levin B., Lieberman D.A., McFarland B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008, 134:1570-1595.
8. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004, 351:2704-2714.
9. Allison J.E. Colorectal cancer screening guidelines: the importance of evidence and transparency. Gastroenterology 2010, 138:1648-1652.
10. Levin B., Lieberman D.A., McFarland B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Cancer J Clin 2008, 58:130-160.
11. Whitlock E.P., Lin J.S., Liles E., et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Tasks Force. Ann Intern Med 2008, 149:638-658.
12. Schlessinger L., Eddy D.M. Archimedes: a new model for simulating health care systems-the mathematical formulation. J Biomed Inform 2002, 35:37-50.
13. Kahn R., Alperin P., Eddy D., et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010, 375:1365-1374.
14. Eddy D.M., Schlessinger L. Validation of the archimedes diabetes model. Diabetes Care 2003, 26:3102-3110.
15. Brandeau M.L. Modeling complex medical decision problems with the Archimedes model. Ann Intern Med 2005, 143:303-304.
16. Dinh T.A., Rosner B.I., Atwood J.C., et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 2011, 4:9-22.
17. Noah-Vanhoucke J., Green L.E., Dinh T.A., et al. Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population. Cancer 2011, 117:3322-3331.
18. Grossman H.L., Schlender A., Alperin P., et al. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma. Curr Med Res Opin 2010, 26:2779-2793.
19. Kahn R., Alperin P., Eddy D., et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010, 375:1365-1374.
20. Eddy D.M., Peskin B., Shcheprov A., et al. Effect of smoking cessation advice on cardiovascular disease. Am J Med Qual 2009, 24:241-249.
21. Green L.E., Dinh T.A., Smith R.A. An estrogen model: the relationship between body mass index, menopausal status, estrogen replacement therapy, and breast cancer risk. Comput Math Methods Med 2012, 2012:792375.
22. Dinh T.A., Alperin P., Walter L.C., et al. Impact of Comorbidity on Colorectal Cancer Screening Cost-effectiveness Study in Diabetic Populations. J Gen Intern Med 2012, 27:730-738.
23. Clinical Outcomes Research Initiative, Accessed 2007. http://www.cori.org.
24. Surveillance Epidemiology and End Results (SEER) program populations, (19692006). NCI, DCCPS, Surveillance Research Program, Cancer Statistics Branch Released February 2009. http://www.seer.cancer.gov/popdata.
25. Tobi M. Polyps as biomarkers for colorectal neoplasia. Front Biosci 1999, 4:D329-D338.
26. Rutter C.M., Yu O., Miglioretti D.L. A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. Stat Med 2007, 26:98-109.
27. Bolin S., Nilsson E., Sjödahl R. Carcinoma of the colon and rectum: growth rate. Ann Surg 1983, 198:151-158.
28. Umetani N., Masaki T., Watanabe T., et al. Retrospective radiographic analysis of nonpedunculated colorectal carcinomas with special reference to tumor doubling time and morphological change. Am J Gastroenterol 2000, 95:1794-1799.
29. Matsui T., Tsuda S., Yao K., et al. Natural history of early colorectal cancer: evolution of a growth curve. Dis Colon Rectum 2000, 43:S18-S22.
30. Welin S., Youker J., Spratt J.S. The rates and patterns of growth of 375 tumors of the large intestine and rectum observed serially by double contrast enema study (Malmö technique). Am J Roentgenol Radium Ther Nucl Med 1963, 90:673-687.
31. Winawer S.J., Zauber A.G., Ho M.N., et al. Prevention of colorectal cancer by colonoscopic polypectomy: the National Polyp Study Workgroup. N Engl J Med 1993, 329:1977-1981.
32. Chao A., Connell C.J., Cokkinides V., et al. Underuse of screening sigmoidoscopy and colonoscopy in a large cohort of US adults. Am J Public Health 2004, 94:1775-1781.
33. Beresford S.A., Johnson K.C., Ritenbaugh C., et al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006, 295:643-654.
34. Atkin W.S., Edwards R., Kralj-Hans I., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010, 375:1624-1633.
35. Lieberman D.A., Weiss D.G., Bond J.H., et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer: Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000, 343:162-168.
36. Winawer S.J., Zauber A.G., Fletcher R.H., et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin 2006, 56:143-159. quiz 184-185.
37. Hundt S., Haug U., Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009, 150:162-169.
38. Morikawa T., Kato J., Yamaji Y., et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005, 129:422-428.
39. Gross C.P., McAvay G.J., Krumholz H.M., et al. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 2006, 145:646-653.
40. Ness R.M., Holmes A.M., Klein R., et al. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999, 94:1650-1657.
41. Siegel J.E., Weinstein M.C., Russell L.B., et al. Recommendations for reporting cost-effectiveness analyses: Panel on Cost-effectiveness in Health and Medicine. JAMA 1996, 276:1339-1341.
42. Parekh M., Fendrick A.M., Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 2008, 27:697-712.
43. Zauber A.G., Lansdorp-Vogelaar I., Knudsen A.B., et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Tasks Force. Ann Intern Med 2008, 149:659-669.
44. Telford J.J., Levy A.R., Sambrook J.C., et al. The cost-effectiveness of screening for colorectal cancer. CMAJ 2010, 182:1307-1313.
45. Quintero E., Castells A., Bujanda L., et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012, 366:697-706.
46. Wilschut J.A., Hol L., Dekker E., et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011, 141:1648-1655.
47. Institute of Medicine and National Research Council. Economic models of colorectal cancer screening in average-risk adults 2005, National Academies Press, Washington, DC. M. Pignone, L. Russell, J. Wagner (Eds.).
48. Seeff L.C., Nadel M.R., Klabunde C.N., et al. Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer 2004, 100:2093-2103.
49. Klabunde C.N., Schenck A.P., Davis W.W. Barriers to colorectal cancer screening among Medicare consumers. Am J Prev Med 2006, 30:313-319.
50. Rim S.H., Joseph D.A., Steele C.B., et al. Colorectal cancer screening: United States, 2002, 2004, 2006, and 2008. MMWR Surveill Summ 2011, 60(Suppl):42-46.
51. Kuntz K.M., Lansdorp-Vogelaar I., Rutter C.M., et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making 2011, 31:530-539.
52. Crotta S., Segnan N., Paganin S., et al. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 2012, 10:633-638.
53. Villavicencio R.T., Rex D.K. Colonic adenomas: prevalence and incidence rates, growth rates, and miss rates at colonoscopy. Semin Gastrointest Dis 2000, 11:185-193.
54. Johns L.E., Houlston R.S. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001, 96:2992-3003.
55. Cottet V., Pariente A., Nalet B., et al. Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology 2007, 133:1086-1092.
56. Giovannucci E., Colditz G.A., Stampfer M.J., et al. Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control 1996, 7:253-263.
57. Giovannucci E., Ascherio A., Rimm E.B., et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995, 122:327-334.
58. Wilson L.S., Lightwood J. Model of estimated rates of colorectal cancer from polyp growth by year of surveillance. J Med Screen 2001, 8:187-196.
59. Butterly L.F., Chase M.P., Pohl H., et al. Prevalence of clinically important histology in small adenomas. Clin Gastroenterol Hepatol 2006, 4:343-348.
60. O'Brien M.J., Winawer S.J., Zauber A.G., et al. The National Polyp Study: patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990, 98:371-379.
61. Shinya H., Wolff W.I. Morphology, anatomic distribution and cancer potential of colonic polyps. Ann Surg 1979, 190:679-683.
62. Scheiden R., Sand J., Pandin M., et al. Colorectal high-grade adenomas: incidence, localization and adenoma-adenocarcinoma ratio in a retrospective and comparative population-based study of 225 consecutive cases between 1988 and 1996. Int J Colorectal Dis 2000, 15:29-34.
63. Hermanek P. Illustrierte Synopsis kolorektaler Tumore 1983, Pharmazeutische Verlagsanstalt, Munich.
64. Hofstad B., Vatn M. Growth rate of colon polyps and cancer. Gastrointest Endosc Clin N Am 1997, 7:345-363.
65. Bolin S., Nilsson E., Sjödahl R. Carcinoma of the colon and rectum: growth rate. Ann Surg 1983, 198:151-158.
66. Rex D.K. Colonoscopy: a review of its yield for cancers and adenomas by indication. Am J Gastroenterol 1995, 90:353-365.
67. Loeve F., Brown M.L., Boer R., et al. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 2000, 92:557-563.
68. Zauber A.G., Lansdorp-Vogelaar I., Wilschut J., et al. Cost-effectiveness of DNA stool testing to screen for colorectal cancer: report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC models 2007. http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=52.
69. Lansdorp-Vogelaar I., van Ballegooijen M., Zauber A.G., et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009, 101:1412-1422.